Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24615063 | 0.92 | ADORA3 (0.56) | CDK1ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL6821050 | 0.80 | CDK1 (0.79) | CDK2CDK9CDK1ADORA3ADORA1 | |
| SCHEMBL5192872 | 0.74 | CDK1 (0.79) | CDK2CDK9CDK1CCNE1 | |
| SCHEMBL5196875 | 0.74 | CDK1 (0.83) | CDK2CDK9CDK1CCNE1 | |
| SCHEMBL5196107 | 0.73 | CDK1 (0.64) | CDK1ADORA3ADORA1ADORA2APPARD | |
| SCHEMBL5193584 | 0.73 | CDK1 (0.61) | CDK1ADORA3ADORA1ADORA2APPARD | |
| SCHEMBL1443862 | 0.73 | CDK1 (0.76) | CDK2CDK9CDK1 | |
| SCHEMBL3295975 | 0.73 | CDK2 (0.66) | CDK2CDK9CDK1CCNE1 | |
| SCHEMBL3677785 | 0.72 | CDK2 (1.00) | CDK2CDK9CDK1CCNE1 | |
| SCHEMBL3302130 | 0.72 | CDK2 (1.00) | CDK2CDK9CDK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | CDK2 3314/4885CDK9 3225/4885CDK1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.